Eli Lily and Boehringer Ingelheim’s (BI) Jardiance (empagliflozin) Shows to Increase Life Span in Adults with T2D and Cardiovascular Disorders

 Eli Lily and Boehringer Ingelheim’s (BI) Jardiance (empagliflozin) Shows to Increase Life Span in Adults with T2D and Cardiovascular Disorders

Eli Lily and Boehringer Ingelheim’s (BI) Jardiance (empagliflozin) Shows to Increase Life Span in Adults with T2D and Cardiovascular Disorders

Shots:

  • Lily and BI reports results of EMPA-REG OUTCOME trial assessing Jardiance (10/25 mg qd) vs PBO, from 42 countries in 7,020 patients with T2D at high risk for cardiovascular events
  • EMPA-REG OUTCOME results: mean survival @age 45 yrs. (32.1 yrs vs 27.6yrs); @age 50,60,70 & 80yrs. (3.1,2.5, 2,1 yrs.)
  • Jardiance is a prescription drug indicated to lower blood sugar & reduce the risk of cardiovascular death in adults with T2D. In 2011, Eli Lily & BI entered into a collaboration agreement to jointly develop Jardiance for T2D

Click here to read full press release/ article | Ref: Eli Lily | Image: Boehringer Ingelheim

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post